F.M. Nagengast

<i>MSH2</i> Mutation Carriers Are at Higher Risk of Cancer Than <i>MLH1</i> Mutation Carriers: A Study of Hereditary Nonpolyposis Colorectal Cancer Families

Hans F. A. Vasen, Astrid Stormorken, Fred H. Menko et al. · Journal of Clinical Oncology · 2001 · 397 citations · Full text

The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC)

Hans F. A. Vasen, E. A. C. M. Sanders, Babs G. Taal et al. · International Journal of Cancer · 1996 · 103 citations · Full text

What is the appropriate screening protocol in Lynch syndrome?

Andrea E. van der Meulen‐de Jong, F.M. Nagengast, Jan H. Kleibeuker et al. · Familial Cancer · 2006 · 35 citations

Early Diagnosis, Medicine, Diagnosis +4

A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease

Ypke van Oosterhout, Liesbeth van Emst, A Schattenberg et al. · Blood · 2000 · 35 citations

Hereditary cancer registries improve the care of patients with a genetic predisposition to cancer: contributions from the Dutch Lynch syndrome registry

Hans F. A. Vasen, Mary E. Velthuizen, Jan H. Kleibeuker et al. · Familial Cancer · 2016 · 28 citations · Full text